Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib

Launched by DUKE UNIVERSITY · Oct 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well magnetic resonance imaging (MRI) can be repeated in patients who have a specific type of brain tumor called low-grade glioma, which is caused by a mutation in a gene known as IDH1. The patients in this study will be receiving a medication called ivosidenib, which is used to treat this type of tumor. The goal is to see if the MRI results are consistent over time, which can help doctors understand how the treatment is working.

To participate in this trial, candidates need to be between 18 and 70 years old, have a confirmed diagnosis of IDH1 mutant low-grade glioma, and be scheduled for an MRI as part of their regular care. They also need to be receiving treatment at the Preston Robert Tisch Brain Tumor Center at Duke. Participants will need to give their consent to join the study and must be able to undergo MRI scans. This study is not yet recruiting participants, but it aims to provide important information about monitoring treatment responses in patients with this type of brain tumor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent prior to beginning specific protocol procedures
• • 2. Scheduled for contrast-enhanced magnetic resonance imaging (MRI) as part of clinical care
• • 3. Histologically IDH1 mutant low-grade glioma (WHO grade 2) and actively receiving ivosidenib
• • 4. Active patient treatment or evaluations at the Preston Robert Tisch Brain Tumor Center at Duke
• • 5. Age ≥18 years and ≤70 years
• • 6. Karnofsky performance index ≥70%
• • 7. Primary treating physician approval
• Exclusion Criteria:
• • 1. Inability to have MRIs